



MC-Rx
Powered by ProCare Rx

In-Focus

October 2021

MC-Rx's P&T Committee and team of dedicated clinicians have recommended the following changes to MC-Rx's National Formulary as of the effective dates shown. These decisions follow their clinical guidance and are based on safety, efficacy, side effect profile, and potential for abuse. While financial impact does not play a key role in the decision of coverage and preliminary placement, the ultimate cost of therapy of the selected products versus that of the other available products in the same therapeutic class is taken into consideration during final placement.

New BRAND Name Drug Additions to the Formulary

Clinical Category	Brand Name	Route or Dose Form	Indications	Formulary Placement	Effective Date
Oncology	Lumakras	Tablet	Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer	Tier 2 with P/A	09/01/2021
Oncology	Truseltiq	Capsule	Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion	Tier 2 with P/A	09/01/2021
Anti-Depressants	Lybalvi	Tablet	Treatment of adults with schizophrenia and for the treatment of adults with bipolar disorder, or manic or mixed episodes	Tier 3 with Step	09/01/2021
Women's Health	Brexafemme	Tablet	Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis	Tier 3 with Step	09/01/2021
Smallpox	Tembexa	Tablet/Liquid	Treatment of smallpox	Tier 3	09/01/2021
Obesity	Wegovy	Injectable	Indicated for chronic weight management for adults with obesity	Tier 2 with P/A	09/01/2021
Alzheimer's	Aduhelm	Injectable	Treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia	Excluded from Coverage	09/01/2021
Oncology	Camcevi	Injectable	Treatment of adult patients with advanced prostate cancer	Tier 2 with P/A	09/01/2021
Women's Health	Myfembree	Tablet	Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)	Tier 3 with Step	09/01/2021

New Drugs for Medical Benefit

Clinical Category	Brand Name Generic Name	Route/DF	Indications	Formulary Placement	Effective Date
Oncology	Rybrevant	Infusion	Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations	Medical	09/01/2021

Generic Releases Within the Next 90 Days

Drug Name	Indication	New Tier/Restriction	Effective Date
Combigan (Brimonidine/Timolol)	Ophthalmic to treat glaucoma	<i>Remain Tier 2</i>	12/2021
Dexilant (Dexlansoprazole)	PPI to Treat GERD and ulcers	<i>Tier 3, OTC/Generics First</i>	12/2021
Restasis (Cyclosporine)	Ophthalmic to treat dry eye	<i>Remain Tier 2</i>	12/2021
Zubsolv (Buprenorphine)	Film to treat opioid dependency	<i>Tier 3 with 1 Step</i>	01/2022
Vigamox (Moxifloxacin)	Ophthalmic to treat eye infections	<i>Tier 3, Generics First</i>	01/2022

Formulary Changes Within the Next 90 Days

Drug	Indication	New Tier	Effective Date
Dayvigo Tablets	Sedative (Hypnotics)	<i>Tier 2 with 1 Step, must try before Belsomra</i>	10/01/2021
Accrufer Capsules	Iron deficiency	<i>Tier 3, OTC/Generics recommended</i>	10/01/2021
Klisyri Ointment	Actinic keratosis	<i>Tier 2 with 1 Step for oral</i>	10/01/2021
Nerivio Device	Treatment of migraines	<i>Tier 2 with 1 Step for Triptan</i>	10/01/2021
Zubsolv Film	Opioid dependency	<i>Tier 3 with 1 Step for Generics</i>	01/01/2022
Qulipta Tablets	Prevention of migraines	<i>Tier 2 with 1 Step for Triptan</i>	01/01/2022

Additional Notes

The two (2) sections above show the expected changes that may occur in the upcoming 90 days. However, generic-equivalent drugs may not always be approved by the FDA, be manufactured by a generic company, or readily available for sale in pharmacies when the brand drug's patent expiration date is reached. In some cases, only one "authorized" generic may be released that costs the same, if not more, than the preferred brand – in such cases the preferred brand may remain in its current tier and the authorized generic may be deemed non-preferred until additional generic equivalent drugs come to market. Additionally, while we list formulary changes that are expected to occur, there may be times where these drugs or others that are not listed may change copay tiers or clinical management criteria due to market events and/or good clinical practice.

Copies of MC-Rx's National Formulary and Pocket Formulary can be found on our website, <http://www.mc-rx.com>, under the "PBM Resources/Drug and Formulary Lists" tab.